Document Detail

Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: Does ethnicity matter?
MedLine Citation:
PMID:  22711349     Owner:  NLM     Status:  In-Data-Review    
Hepatitis C virus genotype 4 (HCV-4) is spreading beyond Africa and the Middle East but data regarding treatment with pegylated interferon alpha and ribavirin of European populations infected with HCV-4 remains limited. Interestingly, European (vs. Egyptian) origin has been associated with lower sustained virological response rates. Hence the aim of this study was to investigate the treatment outcomes of Greek (vs. Egyptian), treatment-naïve patients infected with HCV-4 (subtype a) and to identify factors influencing response rates. One hundred seventy-seven consecutive patients (mean age: 44.6 ± 10.2, males: 143/177; 80.8%, Egyptians: 76/177; 42.9%) treated over a 7-year period at the Hepatology clinics of three tertiary care hospitals in Greece were retrospectively evaluated. Overall, sustained virological response was achieved in 75/177 (42.4%) of the cohort without a significant difference between the two ethnic groups [Greek: 44/101 (43.6%); Egyptian 31/76 (40.8%), P = 0.7598]. In multivariate analysis, it was found that ethnicity was not associated with an impaired response but age ≥45 years [odds ratio (OR): 0.4225, 95% confidence interval (CI): 0.2135-0.8133; P = 0.0134], diabetes (OR: 0.2346, 95% CI: 0.0816-0.0674; P = 0.0071), advanced liver fibrosis (OR: 0.3964, 95% CI: 0.1933-0.8133; P = 0.0116), and treatment suspension (OR: 0.1738, 95% CI: 0.0482-0.6262; P = 0.0075) showed an independent negative association with response to antiviral treatment. In contrast to previous European data suggesting Egyptian ethnicity to be a positive predictor for a sustained virological response, there was no influence of Greek versus Egyptian ethnicity on treatment outcomes. Higher age, advanced liver fibrosis, and diabetes have been shown to reduce significantly response rates in patients infected with HCV-4. J. Med. Virol. 84: 1217-1223, 2012. © 2012 Wiley Periodicals, Inc.
Vasilios Papastergiou; Dimitrios Dimitroulopoulos; Lamprini Skorda; Philippos Lisgos; Ioannis Ketikoglou; Nikolaos Kostas; Stylianos Karatapanis
Related Documents :
18264929 - Lessons for dialysis investigators from the steno-2 study.
11774109 - Evaluation of doqi guidelines: early start of dialysis treatment is not associated with...
9360659 - More than 17 years of peritoneal dialysis: a case report.
20424479 - Multidisciplinary care improves outcome of patients with stage 5 chronic kidney disease.
10504379 - Postoperative peritonitis originating from the duodenum: operative management by intuba...
7503139 - The effect of peroral calcitriol in small doses on mild secondary hyperparathyroidism i...
18563389 - Half-molar sodium-lactate solution has a beneficial effect in patients after coronary a...
18813989 - Socioeconomic predictors of weight loss after laparoscopic roux-y gastric bypass.
23377239 - Catheter-directed thrombolysis with argatroban and tpa for massive iliac and femoropopl...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of medical virology     Volume:  84     ISSN:  1096-9071     ISO Abbreviation:  J. Med. Virol.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-06-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7705876     Medline TA:  J Med Virol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1217-23     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Wiley Periodicals, Inc.
First Department of Internal Medicine, General Hospital of Rhodes, Rhodes, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for ...
Next Document:  Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adult...